Emibetuzumab Biosimilar – Anti-MET, RCCP2 mAb – Research Grade from ProteoGenix; catalogue PX-TA1351; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Emibetuzumab Biosimilar, also known as Anti-MET, RCCP2 mAb, is a monoclonal antibody that has been developed as a potential therapeutic agent for various types of cancers. This biosimilar is designed to target the MET receptor, which is overexpressed in many cancer types and plays a crucial role in tumor growth and progression. In this article, we will discuss the structure, activity, and potential applications of Emibetuzumab Biosimilar as a research-grade antibody.
Emibetuzumab Biosimilar is a recombinant, humanized monoclonal antibody that is produced in mammalian cells. It is composed of two heavy chains and two light chains, with a total molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen-binding Fab regions at the end of the arms and a constant Fc region at the base. The Fab regions are responsible for binding to the MET receptor, while the Fc region mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
The main target of Emibetuzumab Biosimilar is the MET receptor, a tyrosine kinase receptor that is activated by its ligand, hepatocyte growth factor (HGF). Overexpression of MET has been observed in various cancers, including renal cell carcinoma, non-small cell lung cancer, and gastric cancer, and is associated with poor prognosis and resistance to treatment. Emibetuzumab Biosimilar binds to the extracellular domain of MET and blocks its activation by HGF, thereby inhibiting downstream signaling pathways that promote tumor growth and metastasis.
In addition to its direct anti-tumor activity, Emibetuzumab Biosimilar has been shown to enhance the effectiveness of other anti- cancer therapies. Studies have demonstrated that the combination of Emibetuzumab Biosimilar with chemotherapy or other targeted therapies can lead to improved tumor regression and prolonged survival in animal models. This is thought to be due to the ability of Emibetuzumab Biosimilar to sensitize cancer cells to the effects of other treatments by inhibiting the MET signaling pathway.
Emibetuzumab Biosimilar is currently being evaluated in clinical trials for the treatment of various types of cancer, including renal cell carcinoma, non-small cell lung cancer, and gastric cancer. As a research-grade antibody, it is also widely used in preclinical studies to investigate the role of the MET receptor in cancer biology and to assess the potential of Emibetuzumab Biosimilar as a therapeutic agent.
In addition to its potential as a monotherapy, Emibetuzumab Biosimilar is being studied in combination with other anti- cancer therapies. This includes combinations with chemotherapy, immune checkpoint inhibitors, and other targeted therapies. The goal of these studies is to identify the most effective treatment regimens for different types of cancer and to improve patient outcomes.
In summary, Emibetuzumab Biosimilar is a promising research-grade antibody that has the potential to be a valuable therapeutic agent for various types of cancer. Its unique mechanism of action, targeting the MET receptor, makes it a promising candidate for both monotherapy and combination therapy approaches. Ongoing clinical trials will provide further insights into the efficacy and safety of Emibetuzumab Biosimilar, and its potential to improve outcomes for cancer patients.
ProteoGenix catalogue number PX-TA1351. For research use only.
Target: Emibetuzumab Biosimilar – Anti-MET, RCCP2 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Emibetuzumab Biosimilar – Anti-MET, RCCP2 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
